Clinical Trials
38 trialsA Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Janssen Research & Development, LLC
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
ELEVATE
OncoVerity, Inc.
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Massachusetts General Hospital
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
OncoVerity, Inc.
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Bristol-Myers Squibb
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
BEXMAB
Faron Pharmaceuticals Ltd
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
Bristol-Myers Squibb
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Astellas Pharma Inc
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Celgene
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Bristol-Myers Squibb
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
Hikma Pharmaceuticals LLC
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
AGILE
Servier
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
REGAL
Sellas Life Sciences Group
CULMINATE
OncoVerity, Inc.
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
AbbVie
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
TWT-202
Treadwell Therapeutics, Inc
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
University of Colorado, Denver
PEVOLAM
PETHEMA Foundation
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
Akeso
LAM-BDD
University Hospital, Toulouse